Categories
Colon Cancer

Differential treatment options for left- and right-sided mCRC [Video]

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, provides an overview of therapeutic strategies for patients with RAS wildtype metastatic colorectal cancer (mCRC). Whilst there are novel options for patients with left-sided mCRC including combination therapies consisting of anti-EFGR therapies such as panitumumab with mFOLFOX6, more research is needed to provide efficacious options for patients with right-sided mCRC. Immunotherapy is additionally a viable treatment strategy for patients with microsatellite-instable mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Colon Cancer

PARADIGM: Panitumumab plus mFOLFOX6 in RAS wt mCRC [Video]

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the results of the phase III PARADIGM study (NCT02394795), which assessed panitumumab plus mFOLFOX6 as a first-line therapy in patients with RAS wildtype metastatic colorectal cancer (mCRC). Patients were either given panitumumab or bevacizumab with mFOLFOX6, with overall survival being the primary endpoint. Panitumumab resulted in a superior overall survival, especially in patients with left-sided mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Pancreatic Cancer

FOLFIRINOX, gemcitabine + paclitaxel to enhance surgery outcomes for locally advanced PC [Video]

Combined chemotherapy with FOLFIRINOX, gemcitabine and paclitaxel has previously been demonstrated to improve overall-survival (OS) in metastatic pancreatic cancer. Rainer Fietkau, MD, PhD, University Hospital Erlangen, Erlangen, Germany discusses utilizing this chemotherapy regimen to help avoid the development of distant metastases in patients with locally advanced disease during induction chemotherapy to enhance the benefit of surgery. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Colon Cancer

How will the PARADIGM trial change the mCRC treatment landscape? [Video]

The phase III PARADIGM study (NCT02394795) recently demonstrated the efficacy of panitumumab plus mFOLFOX6 in patients with RAS wildtype metastatic colorectal cancer (mCRC). Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, comments on the consequences of the trial findings. Anti-EFGR therapies such as panitumumab should become the standard of care as a first line therapy for RAS wildtype mCRC. However, the current regimen of bevacizumab with mFOLFOX6 may be given to patients if there are concerns with toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Breast Cancer

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer [Video]

Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, provides his highlights in the field of breast cancer presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including highly anticipated results from the DESTINY-Breast04 trial (NCT03734029), which will potentially set the new standard of care in HER2-low breast cancer. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.

Categories
Breast Cancer

AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer [Video]

Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, discusses findings from the phase III AMEERA-6 trial (NCT05128773) of amcenestrant, a selective estrogen receptor degrader (SERD), in patients with HR-positive early breast cancer who have discontinued aromatase inhibitors due to toxicity. Patients either received amcenestrant or tamoxifen, the current standard of care and whilst previous studies have demonstrated initial safety and efficacy in patients, the AMEERA-6 trial will assess durable responses following a 5-year follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Lung Cancer

Unanswered questions regarding the use of IO in NSCLC [Video]

Jarushka Naidoo, MD, John Hopkins University, Baltimore, MD, talks on unanswered questions regarding the use of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), including the uncertain role of immunotherapy (IO) in the early stages of NSCLC and whether there are biomarkers beyond PD-L1 for selecting patients for IO, as well as biomarkers for predicting toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Skin Cancer

Improving response to immune checkpoint blockade in cSCC [Video]

Paolo Bossi, MD, University of Brescia, Brescia, Italy, reflects on ongoing treatment approaches currently under investigation in patients with cutaneous squamous cell carcinoma, including the role of combined systemic immunotherapy and intra-tumoral injection of a modified herpes-simplex virus with the intention to improve response to immune checkpoint blockade. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma [Video]

Sattva Swarup Neelapu, MD, MD Anderson Cancer Center, Houston, TX, provides an overview of the results of ZUMA-12 (NCT03761056), a Phase II trial evaluating axicabtagene ciloleucel (axi-cel) as first-line therapy in high-risk large B-cell lymphoma. The primary endpoint in efficacy-evaluable patients was met, with a 78% complete response rate and an 89% objective response rate. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Breast Cancer

DESTINY-Breast04: practice-changing results for HER2-low breast cancer [Video]

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the practice-changing findings from DESTINY-Breast04 (NCT03734029), a Phase III study that demonstrated improved survival of patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan compared to standard chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Skin Cancer

Remaining hurdles in liquid biopsies [Video]

Susanne Flach, BM BCh, PhD, Ludwig-Maximilians-University, Munich, Germany, reflects on the use of circulating tumor DNA (ctDNA) approaches in head and neck squamous cell carcinoma, highlighting the importance of improving sensitivty, reducing cost of next-generation sequencing and standardization of techniques. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Colon Cancer

DYNAMIC: ctDNA guiding adjuvant chemotherapy in stage II colon cancer [Video]

Jeanne Tie, MBChB, FRACP, MD, Peter MacCallum Cancer Centre and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, discusses the results from the DYNAMIC trial, a study assessing whether a circulating tumor DNA (ctDNA) guided approach could reduce the use of adjuvant chemotherapy in patients with stage II colon cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.